Biodistribution of Chimeric Antibody in Mice and Humans
Author Information
Author(s): N Oriuchi, N Watanabe, S Sugiyama, T Higuchi, K Imai, H Yamanaka, M Hashimoto, H Kanda, K Endo
Primary Institution: Gunma University School of Medicine
Hypothesis
The biodistribution of a chimeric mouse-human monoclonal antibody differs between athymic mice and human patients.
Conclusion
The study found that the chimeric antibody showed significantly different biodistribution in humans compared to the animal model, with a high accumulation in the liver.
Supporting Evidence
- The chimeric antibody showed a high labeling efficiency and stability.
- None of the patients showed adverse reactions after administration.
- The first-phase plasma half-life of the antibody was found to be 6.4 minutes.
- Significantly different biodistribution was observed between the animal model and human patients.
Takeaway
This study looked at how a special antibody behaves in mice and humans, finding that it acts very differently in the two.
Methodology
The study involved labeling a chimeric antibody with technetium-99m and administering it to both athymic mice and human patients to compare biodistribution.
Limitations
The study was limited to a small sample size of four patients.
Participant Demographics
Patients aged 63 to 74 years with metastatic bone tumors from prostate cancer.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website